Let's talk

Engineering the Next Generation of Tumor-Focused Immunotherapy

Designed to neutralize immune suppression and actively stimulate tumor-specific immune activation.

Dr. jay Chaplin Phd

immunologist / inventor

 Reach Out To Dr. Chaplin

Built for the Next Phase of Immunotherapy

The future of cancer treatment lies in smarter immune engineering. Not broader activation. Not higher doses. But focused intervention at the tumor-immune interface.

Dr. Chaplin’s work centers on a multi-function strategy designed to reshape the tumor microenvironment. The following sections outline the core principles behind that approach.

THE CORE IDEA

Immunotherapy Works — But Not for Everyone

Checkpoint inhibitors like PD-1/PD-L1 therapies have transformed cancer care.

But many tumors remain “cold.”

They suppress immune cells.
They prevent activation.
They evade destruction.

Simply removing immune brakes isn’t always enough.

What if you could both remove suppression
and actively stimulate immune attack — in the same place and at the same time?

THE PLATFORM

A multi-Function Tumor-Targeted Construct

Dr. Chaplin is developing engineered protein constructs designed to operate directly at the tumor surface.

The platform is built to:

• Bind preferentially to PD-L1–dense tumor cells, neutralizing suppressive signaling
• Deliver a localized immune-stimulatory signal
• Recruit and activate memory helper T cells to reshape the tumor microenvironment

Rather than only lifting immune restraint,
the strategy is designed to both release the brake and press the accelerator.

WHY IT MATTERS

Designed for Modern Combination Therapy

This platform is not intended to replace existing immunotherapy.

It is designed to complement it.

By combining suppression blockade with targeted immune activation,
the approach aims to reshape the tumor microenvironment
in ways single-mechanism therapies cannot.

Modern oncology is moving toward intelligent combination strategies.
This work is built with that future in mind.

CURRENT STATUS

Development Phase

This therapeutic platform is currently in development.

Dr. Chaplin’s background in immunology and cancer drug design informs the molecular engineering strategy behind the construct design.

Further validation and translational development remain ongoing goals.

The goal

Convert cold tumors into more immunologically active ones —while maintaining tumor-focused precision.

HOW THE PLATFORM WORKS

A Multi-Function Targeted Immunotherapy Construct. 
Dr. Chaplin is developing engineered protein constructs designed to operate directly at the tumor surface.
The platform is built around three core functions:

Tumor-Focused Targeting

The construct preferentially binds to high-density PD-L1 expressed on tumor cells.

• Recognizes multiple copies of PD-L1
• Demonstrates high-avidity binding in dense tumor environments
• Localizes where immune suppression is strongest

This helps concentrate activity at the tumor interface rather than broadly throughout the body.

Neutralization of Immune Suppression

Once bound, the construct interferes with PD-1 / PD-L1 mediated immune inhibition.

• Reduces suppressive signaling
• Disrupts tumor-mediated immune evasion
• Releases localized immune restraint

This addresses one of the dominant mechanisms tumors use to avoid immune destruction, which PD-1 / PD-L1 is the primary example of.

Local Immune Activation

In addition to blocking suppression, the construct includes a grafted stimulatory domain.

This enables:

• Direct promotion of T-cell activation
• Increased immune engagement at the tumor site
• Conversion of “cold” tumors into more inflamed, “hot” immune environments

Rather than only releasing the brake, the platform is designed to release the brake AND press the accelerator.

Long-term Efficacy

Stimulation of memory helper T cells reshapes the tumor microenvironment and gives long-term immune activation specifically at the tumor site.

HOW THIS DIFFERS FROM

STANDARD CHECKPOINT THERAPY

Designed to Do More Than Block Suppression

Standard Checkpoint Inhibitors:

  • Remove immune suppression
  • Require pre-existing immune activity
  • Systemic exposure
  • Single mechanism

Dr. Chaplin's Platform:

  • Remove suppression
  • Actively stimulate immune activation
  • Tumor-focused localization
  • Multi-function construct

Advancing the Future of Tumor Immunotherapy

Translational research requires collaboration.

If you are:

• An investor interested in early-stage therapeutic innovation
• A researcher exploring complementary immune strategies
• A clinician with insight into translational development
• A scientific advisor or biotech leader
• Someone with resources, ideas, or strategic interest

We welcome thoughtful conversation.

Dr. Chaplin’s work is currently in early development, and meaningful progress depends on the right partnerships.

If this platform aligns with your expertise or vision, we would be glad to connect.

Contact Us to Explore Collaboration

 Reach Out to Dr. Chaplin

Stay Informed on Our Emerging Therapeutic Developments

If you would like to stay informed as these new inventions advance and additional programs are launched, sign up here.

 Yes, Sign Me Up